



Marksans Pharma Ltd.

August 20, 2024

BSE Limited

Corporate Relation Department
PhirozeJeejeeboi Towers,
Dalal Street,
Mumbai - 400001.

Scrip Code: 524404

National Stock Exchange of India Limited

Listing Department
Exchange Plaza, C-1, Block-G,
Bandra-Kurla Complex,
Bandra (East), Mumbai - 400051.

Symbol: MARKSANS

Sub: Press Release

Successful closure of US FDA Inspection at Marksans Pharma's manufacturing facility located at Verna, Goa

We refer to our letter dated April 18, 2024 on the inspection conducted by the USFDA at the manufacturing facility of the Company located at Plot No. L-82 & L-83, Verna Industrial estate, Verna, Goa, India from April 09, 2024 to April 17, 2024.

In furtherance to the aforementioned intimation, this is to inform you that the USFDA has issued an Establishment Inspection Report ("EIR") for the said manufacturing facility and the inspection has now been successfully closed by the USFDA. USFDA has determined that the inspection classification of this facility is "Voluntary Action Indicated" (VAI).

For Marksans Pharma Limited

Harshavardhan Panigrahi
Company Secretary

About Marksans Pharma Ltd

Marksans Pharma Limited (www.marksanspharma.com) headquartered at Mumbai, India is engaged in Research, Manufacturing & Marketing of generic pharmaceutical formulation in the global markets. The company's manufacturing facilities located in India, USA and UK are approved by several leading regulatory agencies including USFDA, UKMHRA and Australian TGA. The company's robust product portfolio spreads over major therapeutic segments of CVS, CNS, Anti-diabetic, Pain Management, Upper respiratory and Gastroenterological. The company is marketing these products globally.

Marksans Pharma Ltd.

11th Floor, "GRANDEUR", Opp. Gundecha Symphony, Veera Desai Extension Road, Oshiwara, Andheri (W), Mumbai - 400 053 Tel.: +91 22 4001 2000 E-mail: info@marksanspharma.com
www.marksanspharma.com